We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.82%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.17B
AUM Growth
+$18.3M
Cap. Flow
-$273M
Cap. Flow %
-4.42%
Top 10 Hldgs %
39.22%
Holding
178
New
12
Increased
57
Reduced
71
Closed
15

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$25.8M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
3
EXAS
Exact Sciences
EXAS
+$16.4M
4
ABT icon
Abbott
ABT
+$15.1M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$13M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$36.6M
2
BIO icon
Bio-Rad Laboratories Class A
BIO
+$34.7M
3
CRL icon
Charles River Laboratories
CRL
+$33.2M
4
ARGX icon
argenx
ARGX
+$29.8M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Industrials 0.04%
3 Communication Services 0.02%
4 Technology 0.01%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
126
Protagonist Therapeutics
PTGX
$8.75B
$556K 0.01%
12,346
-2,800
-18% -$113K
APLS
127
DELISTED
Apellis Pharmaceuticals
APLS
$549K 0.01%
19,046
-425,358
-96% -$15.8M
ADMA icon
128
ADMA Biologics
ADMA
$1.92B
$518K 0.01%
25,900
-5,000
-16% -$77.8K
BIIB icon
129
Biogen
BIIB
$29.9B
$511K 0.01%
2,634
-3,268
-55% -$684K
HCM icon
130
HUTCHMED
HCM
$1.89B
$469K 0.01%
24,015
-1,125,142
-98% -$20.3M
DNLI icon
131
Denali Therapeutics
DNLI
$3.67B
$457K 0.01%
+15,700
New +$389K
VTRS icon
132
Viatris
VTRS
$20.1B
$456K 0.01%
39,283
+12,752
+48% +$147K
TVTX icon
133
Travere Therapeutics
TVTX
$5.33B
$434K 0.01%
+31,000
New +$323K
MRUS
134
DELISTED
Merus
MRUS
$400K 0.01%
8,000
-1,800
-18% -$94K
ARQT icon
135
Arcutis Biotherapeutics
ARQT
$3.42B
$367K 0.01%
39,500
+22,000
+126% +$217K
ACLX
136
DELISTED
Arcellx
ACLX
$334K 0.01%
+4,000
New +$266K
XENE icon
137
Xenon Pharmaceuticals
XENE
$6.32B
$323K 0.01%
8,200
-2,000
-20% -$80.6K
NKE icon
138
Nike
NKE
$61.9B
$309K 0.01%
3,500
– –
BPMC
139
DELISTED
Blueprint Medicines
BPMC
$296K ﹤0.01%
3,200
-1,900
-37% -$189K
KURA icon
140
Kura Oncology
KURA
$922M
$266K ﹤0.01%
13,600
+3,600
+36% +$72.9K
BBIO icon
141
BridgeBio Pharma
BBIO
$16.5B
$265K ﹤0.01%
10,400
-2,400
-19% -$63K
MDGL icon
142
Madrigal Pharmaceuticals
MDGL
$12.6B
$233K ﹤0.01%
1,100
– –
IDYA icon
143
IDEAYA Biosciences
IDYA
$3.41B
$228K ﹤0.01%
7,200
+1,500
+26% +$56.9K
RARE icon
144
Ultragenyx Pharmaceutical
RARE
$2.65B
$222K ﹤0.01%
4,000
– –
MLTX icon
145
MoonLake Immunotherapeutics
MLTX
$1.59B
$222K ﹤0.01%
4,400
– –
SMMT icon
146
CALL
Summit Therapeutics
SMMT
$10.9B
$219K ﹤0.01%
+10,000
New +$140K
BIDU icon
147
Baidu
BIDU
$35.8B
$211K ﹤0.01%
2,000
– –
MLYS icon
148
Mineralys Therapeutics
MLYS
$2.35B
$200K ﹤0.01%
16,499
-1,000
-6% -$12.1K
GRMN
149
Garmin
GRMN
$46.9B
$185K ﹤0.01%
1,050
– –
NRIX icon
150
Nurix Therapeutics
NRIX
$2.43B
$180K ﹤0.01%
+8,000
New +$181K
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q3 2024 Portfolio in Review

As of Q3 2024, Bellevue Group held 178 positions worth $6.17B, up 0.3% from $6.15B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Bellevue Group withdrew a net $273M in Q3 2024, closing 15 positions and reducing 71 holdings. Its most notable exit was Silk Road Medical, Inc. Common Stock, an estimated $23.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Terns Pharmaceuticals worth $8.69M.

  • Bellevue Group's largest Q3 2024 buy was Terns Pharmaceuticals: 1,042,135 shares worth $8.69M.
  • Bellevue Group added most to Evolent Health in Q3 2024, an estimated $25.8M increase.
  • Bellevue Group's biggest Q3 2024 reduction was Insmed, cutting an estimated $36.6M.
  • Bellevue Group fully exited Silk Road Medical, Inc. Common Stock in Q3 2024, selling an estimated $23.1M.
  • Bellevue Group's ten largest holdings make up 39% of its $6.17B portfolio in Q3 2024.
  • Bellevue Group opened 12 new positions and closed 15 in Q3 2024.
  • Bellevue Group's portfolio value rose 0.3% quarter-over-quarter to $6.17B.

Based on Bellevue Group's 13F filing for Q3 2024, filed 14 Nov 2024.